

CRITICAL OUTCOME TECHNOLOGIES INVITED TO PRESENT AT 16TH INTERNATIONAL P53 WORKSHOP IN SWEDEN

London, Ontario (June 13th, 2014): Critical Outcome Technologies Inc. (“COTI” or the “Company”) (TSX-V: COT), the bioinformatics and accelerated drug discovery company, announced today that its President and CEO, Dr. Wayne Danter, will be a featured presenter at the 16th International p53 Workshop at the Stockholm Waterfront Congress Centre in Sweden, which runs from June 15-19, 2014. This annual conference brings together world-renowned scientists to discuss novel, basic, transitional, and clinical research in the area of cancer biology with a focus on the p53 tumor suppressor gene.

Dr. Danter’s presentation is scheduled for Monday, June 16 at 3:15 p.m. CEST, and will highlight the Company’s lead cancer drug candidate, COTI-2, as a novel small molecule activator of mutant p53 protein for the treatment of susceptible cancers. While at the conference, Dr. Danter will also be meeting with Professor Sir David Lane, known for his joint discovery of the p53 tumor suppressor protein in 1979.

“I look forward to discussing our extensive preclinical findings regarding COTI-2 with Professor Lane and several other p53 thought leaders and interested parties,” said Dr. Danter. “COTI-2 has a major mechanism of action that is dependent on p53 gene mutation status in human cancer cells. We are convinced that it is only a matter of time before the world recognizes the potentially transformational impact of COTI-2 in the treatment of many cancers where there is a p53 gene mutation present in afflicted patients.”

Following Dr. Danter’s scheduled presentation, the Company will upload his slides to SlideShare at www.slideshare.net/CriticalOutcome.

About Critical Outcome Technologies Inc.

COTI is a leading-edge bioinformatics company specializing in accelerating the discovery and development of small molecules – dramatically reducing the time and cost to bring new drugs to market. COTI’s proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.

For more information, visit www.criticaloutcome.com or contact:

Critical Outcome Technologies Inc.

Dr. Wayne Danter

President & CEO

Tel: 519-858-5157

Email: wdanter@criticaloutcome.com

Heisler Communications

Trevor Heisler

Investor Relations

Tel: 416-500-8061

Email: trevor@heislercommunications.com

Follow @CriticalOutcome on Twitter at <http://twitter.com/CriticalOutcome>

Notice to Readers

Information contained in this press release may contain certain statements, which constitute “forward-looking statements” within the meaning of the Securities Act (Ontario) and applicable securities laws. For example, the statement “... it is only a matter of time before the world recognizes the potentially transformational impact of COTI-2 in the treatment of many cancers where there is a p53 gene mutation present in afflicted patients.” is a forward-looking statement. Forward-looking statements by their nature are not guarantees of future performance and are based upon management’s current expectations, estimates, projections and assumptions. COTI operates in a highly competitive environment that involves significant risks and uncertainties, which could cause actual results to differ materially from those anticipated in these forward-looking statements. Management of COTI considers the assumptions on which these forward-looking statements are based to be reasonable, but as a result of the many risk factors, cautions the reader that actual results could differ materially from those expressed or implied in these forward-looking statements. Information in this press release should be considered accurate only as of the date of the release and may be superseded by more recent information disclosed in later press releases, filings with the securities regulatory authorities or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.